Treatment of amyloidogenic disease

• US 7,588,766 B1
• Filed: 11/28/2000
• Issued: 09/15/2009
• Est. Priority Date: 05/26/2000
• Status: Expired due to Fees

• Current Assignee: Janssen Alzheimer Immunotherapy (Johnson & Johnson)
• Original Assignee: Elan Pharma International Limited (Perrigo Company PLC)
• Inventors: Schenk, Dale B.
• Primary Examiner(s): Kolker; Daniel E.
• Application Number:
  US09/723,765
• Time in Patent Office: 3,213 Days
• Field of Search: 514/2, 424/184.1, 424/185.1, 424/192.1, 424/193.1, 530/300, 530/350
• US Class Current: 424/192.1
• CPC Class Codes: A61K 2039/55505 Inorganic adjuvants
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/55572 Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• CPC Class Codes: A61K 2039/55577 Saponins; Quil A; QS21; ISCOMS
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 39/0007 Nervous system antigens; Prions
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/77 Internalization into the cell

Abstract

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer'"'"'s disease. Preferred agents including N-terminal fragments of Aβ and antibodies binding to the same.

Claims

1. A method of treating a patient having Alzheimer'"'"'s disease, comprising administering to the patient an effective dosage to treat the disease of an N-terminal segment of Aβ

(SEQ ID NO;

42) consisting of residues beginning at residue 1 of Aβ and

ending at residues 7-11 of Aβ and

the segment being linked to a carrier molecule to form a conjugate, wherein the carrier molecule helps elicit an immune response to the N-terminal segment, and wherein if the carrier molecule is a polypeptide the polypeptide is heterologous to Aβ

.

2. The method of claim 1, wherein the conjugate further comprises at least one additional copy of the N-terminal segment.

3. The method of claim 1, wherein the patient has a genetic risk of the disease.

4. The method of claim 1, wherein the patient is human.

5. A method of lessening the severity or delaying the outset of Alzheimer'"'"'s disease in a patient at risk of the disease, comprising administering to the patient a dosage of an N-terminal segment of Aβ

(SEQ ID NO;

42), the segment consisting of residues beginning at residue 1 of Aβ and

ending at residues 7-11 of Aβ and

the segment being linked to a carrier molecule to form a conjugate, wherein the carrier molecule helps elicit an immune response to the N-terminal segment, and wherein if the carrier molecule is a polypeptide the polypeptide is heterologous to Aβ

, and wherein the dosage is effective to lessen the severity or delay the outset of the disease.

6. The method of claim 5, wherein the conjugate further comprises at least one additional copy of the N-terminal segment.

7. The method of claim 5, wherein the patient has a genetic risk of the disease.

8. The method of claim 5, wherein the patient is human.